Aspirin controlled release - New Haven Pharmaceuticals

Drug Profile

Aspirin controlled release - New Haven Pharmaceuticals

Alternative Names: Aspirin slow-release - New Haven Pharmaceuticals; Durlaza; NHP-554C

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New Haven Pharmaceuticals
  • Class Antiplatelets; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cardiovascular disorders; Stroke

Most Recent Events

  • 07 Feb 2017 Aspirin controlled release licensed to Espero Pharmaceuticals worldwide
  • 15 Dec 2015 Launched for Cardiovascular disorders (Prevention) in USA (PO)
  • 15 Dec 2015 Launched for Stroke (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top